Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
详细信息 查看全文
- 作者：Charles Craddock1 ; 2 ; charles.craddock@uhb.nhs.uk" class="auth_mail" title="E-mail the corresponding author ; Nadira Jilani1 ; 2 ; Shamyla Siddique1 ; 2 ; Christina Yap1 ; 2 ; Josephine Khan2 ; Sandeep Nagra1 ; Janice Ward1 ; Paul Ferguson1 ; 2 ; 3 ; Peter Hazlewood1 ; 2 ; Richard Buka1 ; Paresh Vyas4 ; Oliver Goodyear3 ; Eleni Tholouli5 ; Charles Crawley6 ; Nigel Russell7 ; Jenny Byrne7 ; Ram Malladi1 ; 2 ; 3 ; John Snowden8 ; Mike Dennis9
- 关键词：Acute myeloid leukemia ; Relapse ; Azacitidine ; Tumor antigens
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：22
- 期：2
- 页码：385-390
- 全文大小：184 K
文摘
- •
Azacitidine is well tolerated in the majority of patients with acute myeloid leukemia after allogeneic stem cell transplantation.
- •
Administration of post-transplantation azacitidine is associated with a low risk of chronic graft-versus-host disease.
- •
Patients who demonstrate a CD8+ T cell response to tumor antigens demonstrate a lower risk of relapse.